|
1
|
Kakar SS and Jennes L: Expression of
gonadotropin-releasing hormone and gonadotropin-releasing hormone
receptor mRNAs in various non-reproductive human tissues. Cancer
Lett. 98:57–62. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu F, Usui I, Evans LG, Austin DA, Mellon
PL, Olefsky JM and Webster NJ: Involvement of both G(q/11) and G(s)
proteins in gonadotropin-releasing hormone receptor-mediated
signaling in L beta T2 cells. J Biol Chem. 277:32099–32108. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hamm HE: How activated receptors couple to
G proteins. Proc Natl Acad Sci USA. 98:4819–4821. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gilman AG: G proteins: Transducers of
receptor-generated signals. Annu Rev Biochem. 56:615–649. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ford CE, Skiba NP, Bae H, Daaka Y, Reuveny
E, Shekter LR, Rosal R, Weng G, Yang CS, Iyengar R, et al:
Molecular basis for interactions of G protein betagamma subunits
with effectors. Science. 280:1271–1274. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Berridge MJ and Irvine RF: Inositol
trisphosphate, a novel second messenger in cellular signal
transduction. Nature. 312:315–321. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Limor R, Ayalon D, Capponi AM, Childs GV
and Naor Z: Cytosolic free calcium levels in cultured pituitary
cells separated by centrifugal elutriation: Effect of
gonadotropin-releasing hormone. Endocrinology. 120:497–503. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tse FW, Tse A, Hille B, Hille B, Horstmann
H and Almers W: Local Ca2+ release from internal stores
controls exocytosis in pituitary gonadotrophs. Neuron. 18:121–132.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Naor Z, Harris D and Shacham S: Mechanism
of GnRH receptor signaling: Combinatorial cross-talk of
Ca2+ and protein kinase C. Front Neuroendocrinol.
19:1–19. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim Y, Han JM, Park JB, Lee SD, Oh YS,
Chung C, Lee TG, Kim JH, Park SK, Yoo JS, et al: Phosphorylation
and activation of phospholipase D1 by protein kinase C in vivo:
Determination of multiple phosphorylation sites. Biochemistry.
38:10344–10351. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mitchell R, Robertson DN, Holland PJ,
Collins D, Lutz EM and Johnson MS: ADP-ribosylation
factor-dependent phospholipase D activation by the M3 muscarinic
receptor. J Biol Chem. 278:33818–33830. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kolch W, Heidecker G, Kochs G, Hummel R,
Vahidi H, Mischak H, Finkenzeller G, Marmé D and Rapp UR: Protein
kinase C alpha activates RAF-1 by direct phosphorylation. Nature.
364:249–252. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Levi NL, Hanoch T, Benard O, Rozenblat M,
Harris D, Reiss N, Naor Z and Seger R: Stimulation of Jun
N-terminal kinase (JNK) by gonadotropin-releasing hormone in
pituitary alpha T3-1 cell line is mediated by protein kinase C,
c-Src, and CDC42. Mol Endocrinol. 12:815–824. 1998.PubMed/NCBI
|
|
14
|
Mulvaney JM and Roberson MS: Divergent
signaling pathways requiring discrete calcium signals mediate
concurrent activation of two mitogen-activated protein kinases by
gonadotropin-releasing hormone. J Biol Chem. 275:14182–14189. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Seger R and Krebs EG: The MAPK signaling
cascade. FASEB J. 9:726–735. 1995.PubMed/NCBI
|
|
16
|
Maurer RA, Kim KE, Schoderbek WE, Roberson
MS and Glenn DJ and Glenn DJ: Regulation of glycoprotein hormone
alpha-subunit gene expression. Recent Prog Horm Res. 54:455–484;
discussion 485. 1999.PubMed/NCBI
|
|
17
|
Ben-Menahem D, Shraga-Levine Z, Limor R
and Naor Z: Arachidonic acid and lipoxygenase products stimulate
gonadotropin alpha-subunit mRNA levels in pituitary alpha T3-1 cell
line: Role in gonadotropin releasing hormone action. Biochemistry.
33:12795–12799. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shraga-Levine Z, Ben-Menahem D and Naor Z:
Arachidonic acid and lipoxygenase products stimulate protein kinase
C beta mRNA levels in pituitary alpha T3-1 cell line: Role in
gonadotropin-releasing hormone action. Biochem J. 316:667–670.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bliss SP, Navratil AM, Xie J and Roberson
MS: GnRH signaling, the gonadotrope and endocrine control of
fertility. Front Neuroendocrinol. 31:322–340. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Miller RS, Wolfe A, He L, Radovick S and
Wondisford FE: CREB binding protein (CBP) activation is required
for luteinizing hormone beta expression and normal fertility in
mice. Mol Cell Biol. 32:2349–2358. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Khadra A and Li YX: A model for the
pulsatile secretion of gonadotropin-releasing hormone from
synchronized hypothalamic neurons. Biophys J. 91:74–83. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Haisenleder DJ, Dalkin AC, Ortolano GA,
Marshall JC and Shupnik MA: A pulsatile gonadotropin-releasing
hormone stimulus is required to increase transcription of the
gonadotropin subunit genes: Evidence for differential regulation of
transcription by pulse frequency in vivo. Endocrinology.
128:509–517. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qayum A, Gullick W, Clayton RC, Sikora K
and Waxman J and Waxman J: The effects of gonadotrophin releasing
hormone analogues in prostate cancer are mediated through specific
tumour receptors. Br J Cancer. 62:96–99. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Halmos G, Arencibia JM, Schally AV, Davis
R and Bostwick DG: High incidence of receptors for luteinizing
hormone-releasing hormone (LHRH) and LHRH receptor gene expression
in human prostate cancers. J Urol. 163:623–629. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fekete M, Redding TW, Comaru-Schally AM,
Pontes JE, Connelly RW, Srkalovic G and Schally AV: Receptors for
luteinizing hormone-releasing hormone, somatostatin, prolactin, and
epidermal growth factor in rat and human prostate cancers and in
benign prostate hyperplasia. Prostate. 14:191–208. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Limonta P, Dondi D, Moretti RM, Maggi R
and Motta M: Antiproliferative effects of luteinizing
hormone-releasing hormone agonists on the human prostatic cancer
cell line LNCaP. J Clin Endocrinol Metab. 75:207–212.
1992.PubMed/NCBI
|
|
27
|
Dondi D, Limonta P, Moretti RM, Marelli
MM, Garattini E and Motta M: Antiproliferative effects of
luteinizing hormone-releasing hormone (LHRH) agonists on human
androgen-independent prostate cancer cell line DU 145: Evidence for
an autocrine-inhibitory LHRH loop. Cancer Res. 54:4091–4095.
1994.PubMed/NCBI
|
|
28
|
Redding TW and Schally AV: Inhibition of
prostate tumor growth in two rat models by chronic administration
of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc
Natl Acad Sci USA. 78:6509–6512. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tolis G, Ackman D, Stellos A, Mehta A,
Labrie F, Fazekas AT, Comaru-Schally AM and Schally AV: Tumor
growth inhibition in patients with prostatic carcinoma treated with
luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci
USA. 79:1658–1662. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Koppán M, Nagy A, Schally AV, Plonowski A,
Halmos G, Arencibia JM and Groot K: Targeted cytotoxic analog of
luteinizing hormone-releasing hormone AN-207 inhibits the growth of
PC-82 human prostate cancer in nude mice. Prostate. 38:151–158.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Arencibia JM, Schally AV, Halmos G, Nagy
A, Kiaris H and Klaris H: In vitro targeting of a cytotoxic analog
of luteinizing hormone-releasing hormone AN-207 to ES-2 human
ovarian cancer cells as demonstrated by microsatellite analyses.
Anticancer Drugs. 12:71–78. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gnanapragasam VJ, Darby S, Khan MM, Lock
WG, Robson CN and Leung HY and Leung HY: Evidence that prostate
gonadotropin-releasing hormone receptors mediate an
anti-tumourigenic response to analogue therapy in hormone
refractory prostate cancer. J Pathol. 206:205–213. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gründker C, Huschmand Nia A and Emons G:
Gonadotropin-releasing hormone receptor-targeted gene therapy of
gynecologic cancers. Mol Cancer Ther. 4:225–231. 2005.PubMed/NCBI
|
|
34
|
Limonta P, Dondi D, Moretti RM, Fermo D,
Garattini E and Motta M: Expression of luteinizing
hormone-releasing hormone mRNA in the human prostatic cancer cell
line LNCaP. J Clin Endocrinol Metab. 76:797–800. 1993.PubMed/NCBI
|
|
35
|
Moretti RM, Marelli MM, Dondi D, Poletti
A, Martini L, Motta M and Limonta P: Luteinizing hormone-releasing
hormone agonists interfere with the stimulatory actions of
epidermal growth factor in human prostatic cancer cell lines, LNCaP
and DU 145. J Clin Endocrinol Metab. 81:3930–3937. 1996.PubMed/NCBI
|
|
36
|
Marelli MM, Moretti RM, Dondi D, Motta M
and Limonta P: Luteinizing hormone-releasing hormone agonists
interfere with the mitogenic activity of the insulin-like growth
factor system in androgen-independent prostate cancer cells.
Endocrinology. 140:329–334. 1999.PubMed/NCBI
|
|
37
|
Maudsley S, Davidson L, Pawson AJ, Chan R,
López de Maturana R and Millar RP: Gonadotropin-releasing hormone
(GnRH) antagonists promote proapoptotic signaling in peripheral
reproductive tumor cells by activating a Galphai-coupling state of
the type I GnRH receptor. Cancer Res. 64:7533–7544. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kraus S, Levy G, Hanoch T, Naor Z and
Seger R: Gonadotropin-releasing hormone induces apoptosis of
prostate cancer cells: Role of c-Jun NH2-terminal kinase, protein
kinase B, and extracellular signal-regulated kinase pathways.
Cancer Res. 64:5736–5744. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kraus S, Naor Z and Seger R:
Gonadotropin-releasing hormone in apoptosis of prostate cancer
cells. Cancer Lett. 234:109–123. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Choi JH, Gilks CB, Auersperg N and Leung
PC: Immuno-localization of gonadotropin-releasing hormone (GnRH)-I,
GnRH-II, and type I GnRH receptor during follicular development in
the human ovary. J Clin Endocrinol Metab. 91:4562–4570. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Emons G, Ortmann O, Schulz KD and Schally
AV: Growth-inhibitory actions of analogues of Luteinizing hormone
releasing hormone on tumor cells. Trends Endocrinol Metab.
8:355–362. 1997. View Article : Google Scholar
|
|
42
|
Völker P, Gründker C, Schmidt O, Schulz KD
and Emons G: Expression of receptors for luteinizing
hormone-releasing hormone in human ovarian and endometrial cancers:
Frequency, autoregulation, and correlation with direct
antiproliferative activity of luteinizing hormone-releasing hormone
analogues. Am J Obstet Gynecol. 186:171–179. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Emons G, Ortmann O, Becker M, Irmer G,
Springer B, Laun R, Hölzel F, Schulz KD and Schally AV: High
affinity binding and direct antiproliferative effects of LHRH
analogues in human ovarian cancer cell lines. Cancer Res.
53:5439–5446. 1993.PubMed/NCBI
|
|
44
|
Yano T, Pinski J, Halmos G, Szepeshazi K,
Groot K and Schally AV: Inhibition of growth of OV-1063 human
epithelial ovarian cancer xenografts in nude mice by treatment with
luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl
Acad Sci USA. 91:7090–7094. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
So WK, Cheng JC, Poon SL and Leung PC:
Gonadotropin-releasing hormone and ovarian cancer: A functional and
mechanistic overview. FEBS J. 275:5496–5511. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wilkinson SJ, Kucukmetin A, Cross P, Darby
S, Gnanapragasam VJ, Calvert AH, Robson CN and Edmondson RJ:
Expression of gonadotrophin releasing hormone receptor I is a
favorable prognostic factor in epithelial ovarian cancer. Hum
Pathol. 39:1197–1204. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Imai A, Ohno T, Furui T, Takahashi K,
Matsuda T and Tamaya T: Gonadotropin-releasing hormone stimulates
phospholipase C but not protein phosphorylation/dephosphorylation
in plasma membrane from human epithelial ovarian cancer. Int J
Gynecol Cancer. 3:311–317. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shibata S, Sato H, Ota H, Karube A,
Takahashi O and Tanaka T: Involvement of annexin V in
antiproliferative effects of gonadotropin-releasing hormone
agonists on human endometrial cancer cell line. Gynecol Oncol.
66:217–221. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kim KY, Choi KC, Auersperg N and Leung PC:
Mechanism of gonadotropin-releasing hormone (GnRH)-I and
-II-induced cell growth inhibition in ovarian cancer cells: Role of
the GnRH-I receptor and protein kinase C pathway. Endocr Relat
Cancer. 13:211–220. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kimura A, Ohmichi M, Kurachi H, Ikegami H,
Hayakawa J, Tasaka K, Kanda Y, Nishio Y, Jikihara H, Matsuura N, et
al: Role of mitogen-activated protein kinase/extracellular
signal-regulated kinase cascade in gonadotropin-releasing
hormone-induced growth inhibition of a human ovarian cancer cell
line. Cancer Res. 59:5133–5142. 1999.PubMed/NCBI
|
|
51
|
Imai A, Takagi H, Horibe S, Fuseya T and
Tamaya T and Tamaya T: Coupling of gonadotropin-releasing hormone
receptor to Gi protein in human reproductive tract tumors. J Clin
Endocrinol Metab. 81:3249–3253. 1996.PubMed/NCBI
|
|
52
|
Imai A, Horibe S, Takagi A and Tamaya T:
Gi protein activation of gonadotropin-releasing hormone-mediated
protein dephosphorylation in human endometrial carcinoma. Am J
Obstet Gynecol. 176:371–376. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Emons G, Muller V, Ortmann O, Grossmann G,
Trautner U, Stuckrad B, Schulz K and Schally A: Luteinizing
hormone-releasing hormone agonist triptorelin antagonizes signal
transduction and mitogenic activity of epidermal growth factor in
human ovarian and endometrial cancer cell lines. Int J Oncol.
9:1129–1137. 1996.PubMed/NCBI
|
|
54
|
Gründker C, Völker P and Emons G:
Antiproliferative signaling of luteinizing hormone-releasing
hormone in human endometrial and ovarian cancer cells through G
protein alpha(I)-mediated activation of phosphotyrosine
phosphatase. Endocrinology. 142:2369–2380. 2001.PubMed/NCBI
|
|
55
|
Shirahige Y, Cook C, Pinski J, Halmos G,
Nair R and Schally A: Treatment with luteinizing-hormone-releasing
hormone antagonist sb-75 decreases levels of epidermal
growth-factor receptor and its messenger-RNA in ov-1063 human
epithelial ovarian-cancer xenografts in nude-mice. Int J Oncol.
5:1031–1035. 1994.PubMed/NCBI
|
|
56
|
Cho-Clark M, Larco DO, Semsarzadeh NN,
Vasta F, Mani SK and Wu TJ: GnRH-(1–5) transactivates EGFR in
Ishikawa human endometrial cells via an orphan G protein-coupled
receptor. Mol Endocrinol. 28:80–98. 2014. View Article : Google Scholar
|
|
57
|
Szabó I, Bősze S, Orbán E, Sipos É, Halmos
G, Kovács M and Mező G: Comparative in vitro biological evaluation
of daunorubicin containing GnRH-I and GnRH-II conjugates developed
for tumor targeting. J Pept Sci. 21:426–435. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Cheang MC, Voduc D, Bajdik C, Leung S,
McKinney S, Chia SK, Perou CM and Nielsen TO: Basal-like breast
cancer defined by five biomarkers has superior prognostic value
than triple-negative phenotype. Clin Cancer Res. 14:1368–1376.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Gründker C, Föst C, Fister S, Nolte N,
Günthert AR and Emons G: Gonadotropin-releasing hormone type II
antagonist induces apoptosis in MCF-7 and triple-negative
MDA-MB-231 human breast cancer cells in vitro and in vivo. Breast
Cancer Res. 12:R492010. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Sedgley KR, Finch AR, Caunt CJ and McArdle
CA: Intracellular gonadotropin-releasing hormone receptors in
breast cancer and gonadotrope lineage cells. J Endocrinol.
191:625–636. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Limonta P, Montagnani Marelli M, Mai S,
Motta M, Martini L and Moretti RM: GnRH receptors in cancer: From
cell biology to novel targeted therapeutic strategies. Endocr Rev.
33:784–811. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Fekete M, Wittliff JL and Schally AV:
Characteristics and distribution of receptors for
[D-TRP6]-luteinizing hormone-releasing hormone, somatostatin,
epidermal growth factor, and sex steroids in 500 biopsy samples of
human breast cancer. J Clin Lab Anal. 3:137–147. 1989. View Article : Google Scholar
|
|
63
|
Baumann KH, Kiesel L, Kaufmann M, Bastert
G and Runnebaum B: Characterization of binding sites for a
GnRH-agonist (buserelin) in human breast cancer biopsies and their
distribution in relation to tumor parameters. Breast Cancer Res
Treat. 25:37–46. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Moriya T, Suzuki T, Pilichowska M, Ariga
N, Kimura N, Ouchi N, Nagura H and Sasano H: Immunohistochemical
expression of gonadotropin releasing hormone receptor in human
breast carcinoma. Pathol Int. 51:333–337. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Mangia A, Tommasi S, Reshkin SJ, Simone G,
Stea B, Schittulli F and Paradiso A: Gonadotropin releasing hormone
receptor expression in primary breast cancer: Comparison of
immunohistochemical, radioligand and Western blot analyses. Oncol
Rep. 9:1127–1132. 2002.PubMed/NCBI
|
|
66
|
Morgan K, Meyer C, Miller N, Sims AH,
Cagnan I, Faratian D, Harrison DJ, Millar RP and Langdon SP: GnRH
receptor activation competes at a low level with growth signaling
in stably transfected human breast cell lines. BMC Cancer.
11:4762011. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Millar RP, Pawson AJ, Morgan K, Rissman EF
and Lu ZL: Diversity of actions of GnRHs mediated by ligand-induced
selective signaling. Front Neuroendocrinol. 29:17–35. 2008.
View Article : Google Scholar
|
|
68
|
Naor Z and Huhtaniemi I: Interactions of
the GnRH receptor with heterotrimeric G proteins. Front
Neuroendocrinol. 34:88–94. 2013. View Article : Google Scholar
|
|
69
|
Sviridonov L, Dobkin-Bekman M, Shterntal
B, Przedecki F, Formishell L, Kravchook S, Rahamim-Ben Navi L,
Bar-Lev TH, Kazanietz MG, Yao Z, et al: Differential signaling of
the GnRH receptor in pituitary gonadotrope cell lines and prostate
cancer cell lines. Mol Cell Endocrinol. 369:107–118. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Aguila r-Rojas A, Huer ta-Reyes M,
Maya-Núñez G, Arechavaleta-Velásco F, Conn PM, Ulloa-Aguirre A and
Valdés J: Gonadotropin-releasing hormone receptor activates GTPase
RhoA and inhibits cell invasion in the breast cancer cell line
MDA-MB-231. BMC Cancer. 12:5502012. View Article : Google Scholar
|
|
71
|
Goodson AG and Grossman D: Strategies for
early melanoma detection: Approaches to the patient with nevi. J Am
Acad Dermatol. 60:719–735; quiz 736–718. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Moretti RM, Mai S, Montagnani Marelli M,
Bani MR, Ghilardi C, Giavazzi R, Taylor DM, Martini PG and Limonta
P: Dual targeting of tumor and endothelial cells by
gonadotropin-releasing hormone agonists to reduce melanoma
angiogenesis. Endocrinology. 151:4643–4653. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Wen J, Feng Y, Bjorklund CC, Wang M,
Orlowski RZ, Shi ZZ, Liao B, O'Hare J, Zu Y, Schally AV, et al:
Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist
cetrorelix inhibits myeloma cell growth in vitro and in vivo. Mol
Cancer Ther. 10:148–158. 2011. View Article : Google Scholar
|
|
74
|
Ghiringhelli F, Isambert N and Ladoire S:
Degarelix as a new antiangiogenic agent for metastatic colon
cancer? World J Gastroenterol. 19:769–772. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Schreier VN, Pethő L, Orbán E, Marquardt
A, Petre BA, Mező G and Manea M: Protein expression profile of
HT-29 human colon cancer cells after treatment with a cytotoxic
daunorubicin-GnRH-III derivative bioconjugate. PLoS One.
9:e940412014. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Carlson MJ, Thiel KW and Leslie KK: Past,
present, and future of hormonal therapy in recurrent endometrial
cancer. Int J Womens Health. 6:429–435. 2014.PubMed/NCBI
|
|
77
|
Zhang J, Chtcheglova LA, Zhu R,
Hinterdorfer P, Zhang B and Tang J: Nanoscale organization of human
GnRH-R on human bladder cancer cells. Anal Chem. 86:2458–2464.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Conn PM, Janovick JA, Brothers SP and
Knollman PE: ‘Effective inefficiency’: Cellular control of protein
trafficking as a mechanism of post-translational regulation. J
Endocrinol. 190:13–16. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Maya-Núñez G, Janovick JA and Conn PM:
Combined modification of intracellular and extracellular loci on
human gonadotropin-releasing hormone receptor provides a mechanism
for enhanced expression. Endocrine. 13:401–407. 2000. View Article : Google Scholar
|
|
80
|
Conn PM and Janovick JA: Drug development
and the cellular quality control system. Trends Pharmacol Sci.
30:228–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Janovick JA, Patny A, Mosley R, Goulet MT,
Altman MD, Rush TS III, Cornea A and Conn PM: Molecular mechanism
of action of pharmacoperone rescue of misrouted GPCR mutants: The
GnRH receptor. Mol Endocrinol. 23:157–168. 2009. View Article : Google Scholar :
|
|
82
|
Maya-Núñez G, Ulloa-Aguirre A, Janovick JA
and Conn PM: Pharmacological chaperones correct misfolded GPCRs and
rescue function: Protein trafficking as a therapeutic target.
Subcell Biochem. 63:263–289. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Maya-Núñez G, Janovick JA, Ulloa-Aguirre
A, Söderlund D, Conn PM and Méndez JP: Molecular basis of
hypogonadotropic hypogonadism: Restoration of mutant (E(90)K) GnRH
receptor function by a deletion at a distant site. J Clin
Endocrinol Metab. 87:2144–2149. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Janovick JA, Maya-Nunez G and Conn PM:
Rescue of hypogonadotropic hypogonadism-causing and manufactured
GnRH receptor mutants by a specific protein-folding template:
Misrouted proteins as a novel disease etiology and therapeutic
target. J Clin Endocrinol Metab. 87:3255–3262. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Conn PM and Ulloa-Aguirre A:
Pharmacological chaperones for misfolded gonadotropin-releasing
hormone receptors. Adv Pharmacol. 62:109–141. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Janovick JA, Knollman PE, Brothers SP,
Ayala-Yáñez R, Aziz AS and Conn PM: Regulation of G protein-coupled
receptor trafficking by inefficient plasma membrane expression:
Molecular basis of an evolved strategy. J Biol Chem. 281:8417–8425.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Cheung LW and Wong AS:
Gonadotropin-releasing hormone: GnRH receptor signaling in
extrapituitary tissues. FEBS J. 275:5479–5495. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Sánchez CA, Mercado AJ, Contreras HR,
Cabezas JC, Huidobro CC and Castellón EA: Pharmacoperone IN3
enhances the apoptotic effect of leuprolide in prostate cancer
cells by increasing the gonadotropin-releasing hormone receptor in
the cell membrane. Anticancer Drugs. 23:959–969. 2012.PubMed/NCBI
|
|
89
|
Fister S, Günthert AR, Aicher B, Paulini
KW, Emons G and Gründker C: GnRH-II antagonists induce apoptosis in
human endometrial, ovarian, and breast cancer cells via activation
of stress-induced MAPKs p38 and JNK and proapoptotic protein Bax.
Cancer Res. 69:6473–6481. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Cheng CK and Leung PC: Molecular biology
of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their
receptors in humans. Endocr Rev. 26:283–306. 2005. View Article : Google Scholar
|
|
91
|
Janovick JA, Stewart MD, Jacob D, Martin
LD, Deng JM, Stewart CA, Wang Y, Cornea A, Chavali L, Lopez S, et
al: Restoration of testis function in hypogonadotropic hypogonadal
mice harboring a misfolded GnRHR mutant by pharmacoperone drug
therapy. Proc Natl Acad Sci USA. 110:21030–21035. 2013. View Article : Google Scholar : PubMed/NCBI
|
